AVIR
Price
$2.87
Change
+$0.02 (+0.70%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
245.46M
13 days until earnings call
KALV
Price
$12.69
Change
+$0.24 (+1.93%)
Updated
Apr 24, 02:35 PM (EDT)
Capitalization
611.5M
70 days until earnings call
Ad is loading...

AVIR vs KALV

Header iconAVIR vs KALV Comparison
Open Charts AVIR vs KALVBanner chart's image
Atea Pharmaceuticals
Price$2.87
Change+$0.02 (+0.70%)
Volume$7.77K
Capitalization245.46M
KalVista Pharmaceuticals
Price$12.69
Change+$0.24 (+1.93%)
Volume$600
Capitalization611.5M
AVIR vs KALV Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. KALV commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and KALV is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (AVIR: $2.84 vs. KALV: $12.45)
Brand notoriety: AVIR and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 127% vs. KALV: 71%
Market capitalization -- AVIR: $245.46M vs. KALV: $611.5M
AVIR [@Biotechnology] is valued at $245.46M. KALV’s [@Biotechnology] market capitalization is $611.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than AVIR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 5 TA indicator(s) are bullish while KALV’s TA Score has 7 bullish TA indicator(s).

  • AVIR’s TA Score: 5 bullish, 5 bearish.
  • KALV’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, KALV is a better buy in the short-term than AVIR.

Price Growth

AVIR (@Biotechnology) experienced а -5.27% price change this week, while KALV (@Biotechnology) price change was +6.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.86%. For the same industry, the average monthly price growth was -5.44%, and the average quarterly price growth was -12.23%.

Reported Earning Dates

AVIR is expected to report earnings on Aug 06, 2025.

KALV is expected to report earnings on Jul 03, 2025.

Industries' Descriptions

@Biotechnology (+7.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($612M) has a higher market cap than AVIR($245M). KALV YTD gains are higher at: 46.989 vs. AVIR (-15.164). KALV has higher annual earnings (EBITDA): -173.23M vs. AVIR (-192.53M). AVIR has more cash in the bank: 455M vs. KALV (253M). AVIR has less debt than KALV: AVIR (1.64M) vs KALV (5.78M). AVIR (0) and KALV (0) have equivalent revenues.
AVIRKALVAVIR / KALV
Capitalization245M612M40%
EBITDA-192.53M-173.23M111%
Gain YTD-15.16446.989-32%
P/E RatioN/AN/A-
Revenue00-
Total Cash455M253M180%
Total Debt1.64M5.78M28%
FUNDAMENTALS RATINGS
AVIR vs KALV: Fundamental Ratings
AVIR
KALV
OUTLOOK RATING
1..100
5421
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
9783
SMR RATING
1..100
9196
PRICE GROWTH RATING
1..100
7641
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (46) in the Biotechnology industry is in the same range as KALV (58) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

KALV's Profit vs Risk Rating (83) in the Pharmaceuticals Other industry is in the same range as AVIR (97) in the Biotechnology industry. This means that KALV’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's SMR Rating (91) in the Biotechnology industry is in the same range as KALV (96) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for AVIR (76) in the Biotechnology industry. This means that KALV’s stock grew somewhat faster than AVIR’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that AVIR’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRKALV
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 15 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ELGAX6.32N/A
N/A
Columbia Select Large Cap Growth A
HDRVX16.14N/A
N/A
Janus Henderson Responsible Intl DivN
PBSIX12.44N/A
N/A
Polen US Small Company Growth Instl
RLGYX9.45N/A
N/A
Russell Inv Global Equity Y
SSFRX395.00N/A
N/A
State Street Equity 500 Index R

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+1.22%
ATXS - KALV
46%
Loosely correlated
+12.55%
IDYA - KALV
44%
Loosely correlated
+0.91%
TRDA - KALV
43%
Loosely correlated
N/A
AVIR - KALV
43%
Loosely correlated
-0.98%
ATOS - KALV
42%
Loosely correlated
+11.25%
More